Office Number: 203-815-5782
CaroGen Expands its Board of Directors and Development Leadership Team
Farmington, CT - April 17, 2017: CaroGen today announced an important addition to its Board of Directors (Dr. Jo Viney) and two key senior executive level scientists (Dr. Steven Mason and Dr. Timur Yarovinsky) to its immunotherapy discovery and development team. Click here to read the full press release
CaroGen and University of Connecticut Colon Cancer Immunotherapy Collaboration Highlighted in Colon Cancer News Today
Farmington, CT - January 26, 2017: CaroGen and researchers at the University of Connecticut have initiated a collaboration on development of a colon cancer immunotherapy. This collaboration was highlighted in Colon Cancer News Today. Click here to read the full article.
UCONN Health Researchers Collaborate with CaroGen Corporation to Develop Vaccine to Treat Colon Cancer
Farmington, CT - November 8, 2016: The University of Connecticut and CaroGen Corporation, an emerging immunotherapy company, today announced a collaboration aimed at developing a therapeutic vaccine for treatment of patients with colon cancer. CaroGen’s proprietary technology platform will be applied to a specific target studied by UConn Health’s Dr. Kepeng Wang Ph.D., Assistant Professor of Immunology. Click here to read the full press release
CaroGen Forms Zika Vaccine Consortium
Farmington, CT - November 7, 2016: CaroGen Corporation, announced today that it has formed a consortium comprising CaroGen, the University of Connecticut and Yale University School of Medicine scientists to accelerate the development of a Zika virus vaccine. Click here to read the full press release.
CaroGen Raiess $1M in Series A Funds
Farmington, CT - October 19, 2016: CaroGen Corporation announced today that it has raised $1 million dollars through GP Fortune Investment Partners (GPFI), LLC, to advance the company's Heptatis B Virus (HBV) immunotherapy. Click here to read the full press release.
CaroGen in the News:
August 8, 2016: CaroGen’s CEO Bijan Almassian was profiled by the Hartford Business Journal where he discusses CaroGen's technology, products to treat or prevent Hepatitis B, Zika and C. difficile infections and financing. Click here to read the full interview.
July 5, 2016: Connecticut Senators Murphy and Blumenthal pushing for Zika virus response funding. Click here for the story.
SPARK Commercialization Grant Award for C. difficile Vaccine
Farmington, CT - April 18, 2016: CaroGen announced today that University of Connecticut collaborator, Dr. Kamal Khanna, was awarded a SPARK Commercialization Fund grant from the University of Connecticut. The grant is to support the research and development of a VLV-based vaccine against C. difficile infection. The award will support the creation of candidate VLV vaccines and testing their immunogenicity in preclinical models. Click here to read the award notification from SPARK.
CT Backs CaroGen’s Quest to Fight Cancer, Hepatitis B
March 7, 2016: An interview with CaroGen’s President and CEO was published in the Hartford Business Journal where he provides an update on CaroGen’s product development: Click here to read the full interview.
CaroGen Announces Publication of HBV Vaccine Preclinical Research
Hamden CT - August 17, 2015 - CaroGen Corporation, an emerging vaccine company, today announced the electronic publication of a research article entitled “Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection,” which appeared in the August online issue of the Journal of Virology.
CaroGen Fostering Vaccine Development Collaborations with Yale & UConn and Establishing Laboratory
Farmington CT – January 5, 2015 – CaroGen Corporation today announced that it has chosen UConn’s Technology Incubation Program (TIP) in Farmington to establish a laboratory footprint. This expansion will allow CaroGen to more aggressively pursue the advancement of its proprietary virus-like vesicle (VLV) vaccine technology, development of its HBV vaccine program and evaluation of other potential candidate infectious disease vaccines.
CaroGen Receives $500,000 Investment from Connecticut Bioscience Innovation Fund (CBIF)
Hamden CT – December 10, 2014 – CaroGen has been awarded $500,000 from the CBIF to support the continued development of CaroGen's therapeutic Hepatitis B Virus (HBV) vaccine.
CaroGen Wins Entrepreneur Innovation Award from CTNext
Hamden CT – April 3, 2014 – CaroGen was awarded a $10,000 grant by CTNext, a component of Connecticut’s innovation ecosystem to support the success of companies and entrepreneurs, to further support development of its therapeutic vaccine for chronic Hepatitis B (CHB) viral infection.
The Company’s vaccine platform is a proprietary replication-competent, virus-like vesicle (VLV) technology pioneered by Dr. John Rose of Yale University School of Medicine. The VLV technology is a hybrid combination of components from two unrelated animal viruses: the alphavirus Semliki Forest virus (SFV) and rhabdovirus vesicular stomatitis virus (VSV).
The VLVs generated are capable of entering into cells of the vaccinated subject where they harmlessly propagate to produce the vaccine antigens to be presented to the host immune system. Unlike other viral-based vector vaccines, human infection with these viruses (i.e. SFV and VSV) is rare, so the general population is free of pre-existing, virus-neutralizing antibodies that could compromise vaccine efficacy.
VLV-based nanoparticle vaccines possess the attributes that may comprise a far superior product, that is, offer more effective protection and long-lasting immunity against chronic infections than that seen with the current vaccine technologies. The immune response induced by VLV vaccines has the potential to improve efficacy in individuals known to have less than robust immune responses, notably, children, the elderly and the immune-compromised.
Figure 1: Diagram of the hybrid Alphavirus-Rhabdovirus vector: Semliki Forest virus-vesicular stomatitis virus (SFV-VSV), SFV vector containing the sequence of the gene coding for VSV glycoprotein (G) downstream of subgenomic RNA promoter, sgPr (indicated by curved arrow). Upon infection of a cell with SFV-VSV, G protein will be expressed in the endoplasmic reticulum (ER) and transported through Golgi to the plasma membrane. Unspecific interactions between the G cytoplasmic domain and SFV-VSV RNA leads to the release of “vesicles” or virus-like vesicles (VLVs) able to transfer vector RNA to new cells.